An International Expert Survey on the Indications and Practice of Radical Thoracic Reirradiation for Non-Small Cell Lung Cancer.
Robert Rulach,Robert Rulach,David Ball,Kevin L.M. Chua,Max Dahele,Dirk De Ruysscher,Kevin Franks,Daniel R. Gomez,Matthias Guckenberger,Gerard G Hanna,Alexander V. Louie,Drew Moghanaki,David A. Palma,Clive Peedell,Ahmed Salem,Shankar Siva,Gregory M.M. Videtic,Anthony J. Chalmers,Anthony J. Chalmers,Stephen Harrow,Stephen Harrow +20 more
TL;DR: In this paper, the Delphi consensus process was used to develop expert consensus guidance on the safe practice of treating non-small cell lung cancer with radiation therapy in the setting of prior thoracic irradiation.
read more
Abstract: Purpose Thoracic reirradiation for non-small cell lung cancer with curative intent is potentially associated with severe toxicity. There are limited prospective data on the best method to deliver this treatment. We sought to develop expert consensus guidance on the safe practice of treating non-small cell lung cancer with radiation therapy in the setting of prior thoracic irradiation. Methods and Materials Twenty-one thoracic radiation oncologists were invited to participate in an international Delphi consensus process. Guideline statements were developed and refined during 4 rounds on the definition of reirradiation, selection of appropriate patients, pretreatment assessments, planning of radiation therapy, and cumulative dose constraints. Consensus was achieved once ≥75% of respondents agreed with a statement. Statements that did not reach consensus in the initial survey rounds were revised based on respondents’ comments and re-presented in subsequent rounds. Results Fifteen radiation oncologists participated in the 4 surveys between September 2019 and March 2020. The first 3 rounds had a 100% response rate, and the final round was completed by 93% of participants. Thirty-three out of 77 statements across all rounds achieved consensus. Key recommendations are as follows: (1) appropriate patients should have a good performance status and can have locally relapsed disease or second primary cancers, and there are no absolute lung function values that preclude reirradiation; (2) a full diagnostic workup should be performed in patients with suspected local recurrence and; (3) any reirradiation should be delivered using optimal image guidance and highly conformal techniques. In addition, consensus cumulative dose for the organs at risk in the thorax are described. Conclusions These consensus statements provide practical guidance on appropriate patient selection for reirradiation, appropriate radiation therapy techniques, and cumulative dose constraints.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus on re-irradiation: definition, reporting, and clinical decision making.
Nicolaus Andratschke,J. S. Willmann,Ane L Appelt,Najlaa Alyamani,Panagiotis Balermpas,Brigitta G. Baumert,Coen W. Hurkmans,Morten Høyer,Johannes A. Langendijk,Orit Kaidar-Person,Yvette M. van der Linden,Icro Meattini,Maximilian Niyazi,Nick Reynaert,Dirk De Ruysscher,Stephanie Tanadini-Lang,Peter Hoskin,Philip Poortmans,Carsten Nieder +18 more
TL;DR: In this article , a consensus on re-irradiation aims to assist in re-IRradiation decision-making, and to standardise the classification of different forms of re-rradiation and reporting.
76
Re-irradiation in clinical practice: results of an international patterns of care survey within the framework of the ESTRO-EORTC E2-RADIatE platform.
J. S. Willmann,Ane L Appelt,Panagiotis Balermpas,Brigitta G. Baumert,Dirk de Ruysscher,Morten Høyer,Coen W. Hurkmans,Orit Kaidar-Person,Icro Meattini,Maximilian Niyazi,Philip Poortmans,Nick Reynaert,S. Tandini-Lang,Yvette van der Linden,Carsten Nieder,Nicolaus Andratschke +15 more
TL;DR: This study highlights the heterogeneity in re-irradiation practices across anatomical regions and emphasizes the need for high-quality evidence from prospective studies to guide treatment decisions and derive safe cumulative dose constraints.
20
Treatment plan optimisation for reirradiation.
Louise Murray,C.M. Thompson,C. Pagett,J. Lilley,B. Al-Qaiseh,Stina Svensson,Kjell Eriksson,M. Nix,Michaela A Aldred,Lynn Aspin,Stephen Gregory,Ane L Appelt +11 more
TL;DR: The support tool for re-irradiation Decisions guided by Radiobiology (STRIDeR) project aims to create a clinically viable re-radiation planning pathway within a commercial treatment planning system (TPS), taking fractionation effects, tissue recovery and anatomical changes into account as mentioned in this paper .
14
An international Delphi consensus for pelvic stereotactic ablative radiotherapy re-irradiation.
Finbar Slevin,K. Aitken,Filippo Alongi,Stefano Arcangeli,Eliot Chadwick,Ah Ram Chang,Patrick Cheung,Christopher Crane,Matthias Guckenberger,Barbara Alicja Jereczek-Fossa,Sophia C. Kamran,Rémy Kinj,Mauro Loi,Anand Mahadevan,Mariangela Massaccesi,Lucas C. Mendez,Rebecca Muirhead,David Pasquier,Antonio Pontoriero,Daniel E. Spratt,Y. Tsang,Michael J. Zelefsky,J. Lilley,P. Dickinson,Maria A. Hawkins,Ann Henry,L. Murray +26 more
TL;DR: In this article, an international Delphi study was performed to develop statements to guide practice regarding patient selection, pre-treatment investigations, treatment planning, delivery and cumulative organs at risk (OARs) constraints.
12
Management of reirradiations: A clinical and technical overview based on a French survey.
TL;DR: In this article , a group of physician and physicists developed a survey gathering major issues of the topic of re-radiation, which consisted in four parts: data collection, demographic, clinical and technical aspects.
6
References
Stereotactic Body Radiation Therapy for Inoperable Early Stage Lung Cancer
Robert Timmerman,Rebecca Paulus,James M. Galvin,Jeff M. Michalski,William L. Straube,Jeffrey D. Bradley,Achilles J. Fakiris,Andrea Bezjak,Gregory M.M. Videtic,David W. Johnstone,Jack F. Fowler,Elizabeth Gore,Hak Choy +12 more
TL;DR: Patients with inoperable non-small cell lung cancer who received stereotactic body radiation therapy had a survival rate of 55.8% at 3 years, high rates of local tumor control, and moderate treatment-related morbidity.
2.4K
Sequential vs Concurrent Chemoradiation for Stage III Non–Small Cell Lung Cancer: Randomized Phase III Trial RTOG 9410
Walter J. Curran,Rebecca Paulus,Corey J. Langer,Ritsuko Komaki,Jin S. Lee,Stephen L. Hauser,Stephen L. Hauser,Benjamin Movsas,Benjamin Movsas,Todd H. Wasserman,Seth A. Rosenthal,Elizabeth Gore,Mitchell Machtay,William T. Sause,James D. Cox +14 more
TL;DR: Concurrent delivery of cisplatin-based chemotherapy with TRT confers a long-term survival benefit compared with the sequential delivery of these therapies.
1.1K
Safety and Efficacy of a Five-Fraction Stereotactic Body Radiotherapy Schedule for Centrally Located Non-Small-Cell Lung Cancer: NRG Oncology/RTOG 0813 Trial.
Andrea Bezjak,Rebecca Paulus,Laurie E. Gaspar,Robert Timmerman,William L. Straube,William F. Ryan,Yolanda I. Garces,Anthony T. Pu,Anurag K. Singh,Gregory M.M. Videtic,Ronald C. McGarry,Puneeth Iyengar,Jason Pantarotto,James J. Urbanic,Alexander Y. Sun,Megan E. Daly,Inga S. Grills,Paul W. Sperduto,Daniel P. Normolle,Jeffrey D. Bradley,Hak Choy +20 more
TL;DR: Outcomes in this medically inoperable group of mostly elderly patients with comorbidities were comparable with that of patients with peripheral early-stage tumors, and the MTD for this study was 12.0 Gy/fx; it was associated with 7.2% DLTs and high rates of tumor control.
Hyperfractionated or accelerated radiotherapy in lung cancer: an individual patient data meta-analysis.
Audrey Mauguen,Cécile Le Péchoux,Michele I. Saunders,Steven E. Schild,Andrew T. Turrisi,Michael Baumann,William T. Sause,David Ball,Chandra P. Belani,James A. Bonner,A. Zajusz,Suzanne E. Dahlberg,Matthew Nankivell,Sumithra J. Mandrekar,Rebecca Paulus,Katarzyna Behrendt,Rainer Koch,James F. Bishop,Stanley Dische,Rodrigo Arriagada,Rodrigo Arriagada,Dirk De Ruysscher,Jean Pierre Pignon +22 more
TL;DR: Patients with nonmetastatic NSCLC derived a significant OS benefit from accelerated or hyperfractionated radiotherapy; a similar but nonsignificant trend was observed for SCLC; as expected, there was increased acute esophageal toxicity.
Long-term Follow-up on NRG Oncology RTOG 0915 (NCCTG N0927): A Randomized Phase 2 Study Comparing 2 Stereotactic Body Radiation Therapy Schedules for Medically Inoperable Patients With Stage I Peripheral Non-Small Cell Lung Cancer.
Gregory M.M. Videtic,Rebecca Paulus,Anurag K. Singh,Joe Y. Chang,William Parker,Kenneth R. Olivier,Robert Timmerman,Ritsuko Komaki,James J. Urbanic,Kevin L. Stephans,Sue S. Yom,Clifford G. Robinson,Chandra P. Belani,Puneeth Iyengar,Munther Ajlouni,Darindra D. Gopaul,Jorge B. Gomez Suescun,Ronald C. McGarry,Hak Choy,Jeffrey D. Bradley +19 more
TL;DR: No excess in late-appearing toxicity was seen in either arm and a median survival time of 4 years for each arm suggests similar efficacy, pending any larger studies appropriately powered to detect survival differences.
Related Papers (5)
Wai Tong Ng,Yoke Lim Soong,Yong Chan Ahn,Hussain AlHussain,Horace C.W. Choi,June Corry,Vincent Grégoire,Kevin J. Harrington,Chaosu Hu,Kenneth Jensen,Dora L.W. Kwong,Johannes A. Langendijk,Quynh-Thu Le,Nancy Y. Lee,Jin-Ching Lin,Tai Xiang Lu,William M. Mendenhall,Brian O'Sullivan,Enis Ozyar,Jianji Pan,Lester J. Peters,Sharon Shuxian Poh,David I. Rosenthal,Giuseppe Sanguineti,Yungan Tao,Joseph Wee,Sue S. Yom,Melvin L.K. Chua,Anne W.M. Lee +28 more
Barbara Alicja Jereczek-Fossa,Giulia Marvaso,Mattia Zaffaroni,Simone Giovanni Gugliandolo,Dario Zerini,Federica Corso,Sara Gandini,Filippo Alongi,Alberto Bossi,Philip Cornford,Berardino De Bari,Valérie Fonteyne,Peter Hoskin,Bradley R. Pieters,Alison Tree,Stefano Arcangeli,Donald B. Fuller,Ciro Franzese,Jean-Michel Hannoun-Levi,Guillaume Janoray,Linda G W Kerkmeijer,Young Kwok,Lorenzo Livi,Mauro Loi,Raymond Miralbell,David Pasquier,Michael Pinkawa,Nathaliel Scher,Marta Scorsetti,Mohamed Shelan,A. Toledano,Nicholas van As,Andrea Vavassori,Thomas Zilli,Matteo Pepa,Piet Ost +35 more